Navigation Links
Sirius Genomics Announces Appointment of Senior Director of Business Development
Date:6/30/2010

VANCOUVER, June 30 /PRNewswire/ - Sirius Genomics, a developer of pharmacogenomic diagnostics, announced today that Kamran Alam has been appointed Senior Director of Business Development.

"Sirius Genomics is on track with our existing products and looking to grow our pipeline. Kam's extensive background in partnering with both global pharmaceutical and medical device companies as well as experience in building collaborations with academic and translational research centers will support our commercialization initiatives and product pipeline development," stated Chris Wagner, President and CEO of Sirius Genomics.

Mr. Alam has over 12 years experience in the biotech and medical device industry, during which time he has worked in several therapeutic areas in the roles of Business Development and Finance. Prior to joining Sirius Genomics, Mr. Alam held positions in business development at the Centre for Drug Research and Development, Angiotech Pharmaceuticals, and AnorMED Inc., and has successfully completed numerous and varied partnering deals, mergers and acquisitions, licensing transactions, and has executed extensive business development initiatives in the U.S., Europe and Asia.

Mr. Alam's professional experience also includes roles with PricewaterhouseCoopers LLP Chartered Accountants. A member of the Institute of Chartered Accountants of British Columbia, Mr. Alam holds an MBA Degree, specializing in International Business and Strategy, and a Bachelor of Science Degree, specializing in Cell Biology and Genetics.

About Sirius Genomics: www.siriusgenomics.com

Sirius Genomics is a drug-enabling company that develops pharmacogenomic (PGx) diagnostics that lead to better patient outcomes through personalized medicine. Sirius generates value by improving the safety and effectiveness of pharmaceutical compounds. The Company correlates patient genetics with clinical outcomes, leading to proprietary and commercially viable PGx products that enable better drug treatment. The Company's first product is a genetic predictor of response to treatment for sepsis, a severe blood infection.

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.


'/>"/>
SOURCE Sirius Genomics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sirius Genomics Announces New Collaboration with UK Critical Care Genomics Group
2. Sirius Genomics to Present at Invest Northwest Conference
3. Sirius Genomics Announces 2009 Board of Directors
4. Dr. Robert Lanza is Featured Guest on Deepak Chopras SIRIUS XM Stars Radio Show
5. Sirius Genomics Announces Change in Leadership
6. Learn Proven Practices to Measure, Align and Transform at SiriusDecisions Sales and Marketing Summit 2010
7. Industry Leaders from Blue Coat, Oracle, Polycom, Siemens and Taleo Headline SiriusDecisions Sales and Marketing Summit 2010
8. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
9. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
10. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
11. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... Seattle, WA (PRWEB) , ... June 23, 2016 ... ... technology, announces the release of its second eBook, “Clinical Trials Patient Recruitment and ... patient recruitment and retention in this eBook by providing practical tips, tools, and ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... MA (PRWEB) , ... June 23, 2016 , ... ... Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute ... platform of microbial tests introduced last year,” stated Bob Salter, Vice President of ...
Breaking Biology Technology:
(Date:5/16/2016)...   EyeLock LLC , a market leader of ... an IoT Center of Excellence in Austin, ... of embedded iris biometric applications. EyeLock,s iris ... security with unmatched biometric accuracy, making it the most ... EyeLock,s platform uses video technology to deliver a fast ...
(Date:5/9/2016)... , UAE, May 9, 2016 ... it comes to expanding freedom for high net worth ... Even in today,s globally connected world, there is still ... system could ever duplicate sealing your deal with a ... second passports by taking advantage of citizenship via investment ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
Breaking Biology News(10 mins):